Skip to main content
HR 5605 115th Congress House Health Congressional oversight Drug therapy Drug trafficking and controlled substances Drug, alcohol, tobacco use Government studies and investigations Health care quality Health personnel Health programs administration and funding Home and outpatient care Hospital care Medicare Mental health Performance measurement Prescription drugs User charges and fees

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

Introduced: April 24, 2018 Introduced by: Ruiz, Raul Democratic · California See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 16 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 20, 2018
Received in the Senate and Read twice and referred to the Committee on Finance.
Jun 19, 2018
The title of the measure was amended. Agreed to without objection.
Jun 19, 2018
Motion to reconsider laid on the table Agreed to without objection.
Jun 19, 2018
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)
Jun 19, 2018
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)
Jun 19, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.
Jun 19, 2018
Considered under suspension of the rules. (consideration: CR H5239-5243)
Jun 19, 2018
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Jun 12, 2018
Placed on the Union Calendar, Calendar No. 578.
Jun 12, 2018
Committee on Ways and Means discharged.
Jun 12, 2018
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.
May 17, 2018
Ordered to be Reported (Amended) by Voice Vote.
May 17, 2018
Committee Consideration and Mark-up Session Held.
May 1, 2018
Referred to the Subcommittee on Health.
Apr 24, 2018
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 24, 2018
Introduced in House
 Plain-English summary Congressional Research Service

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

(Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures.

Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants.

(Sec. 3) The bill also requires prescriptions for controlled substances that are covered under the Medicare prescription drug benefit or Medicare Advantage prescription drug plans to be transmitted via electronic prescription programs. The CMS may waive such requirements under specified circumstances.

What's happening now June 20, 2018

Received in the Senate and Read twice and referred to the Committee on Finance.

 Committees of jurisdiction 4
 Cosponsors 1
All 1 Republican 1